May 9, 2026 • 38 mins
Zombie cells sound like a metaphor, but cellular senescence is real biology that can quietly damage tissue through chronic inflammation and toxic secretions. We trace how senolytics work at the molecular level, why dosing has to be pulsed, and why the future looks more like precision maintenance than a magic anti-aging pill.
• what cellular senescence is and why it starts as tumor protection
• how senescent cells resist apoptosis through BCL2 family survival networks
• how SASP drives extracellular matrix breakdown, inflammaging, and nearby cell senescence
• how dasatinib plus quercetin targets senescent cells and why quercetin can act as a pro-oxidant via the Fenton reaction
• why fisetin dosing is pharmacologic and why “food sources” and many supplements miss the mark
• why senolytics use hit-and-run pulses and the real risks of continuous pathway inhibition
• what mouse data in diabetic kidney disease suggests about fibrosis and geroprotective factors
• what the Mayo Clinic trial in healthy women reveals about a senescence threshold and who is likely to benefit
• why a knee osteoarthritis injection failed clinically even if it hit the biological target
• why localized delivery is winning in areas like diabetic macular edema and dermatology
Keep learning, keep questioning, and we'll catch you on the next deep dive.
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Listen
Watch
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
SPEAKER_00 (00:00):
So, uh, you're just sitting there right now, maybe
you're driving, or I don't know,maybe you're making coffee.
You feel totally normal.
But inside your tissues, yeah,like literally right this
second, there are undead cells.
SPEAKER_01 (00:14):
Undead.
SPEAKER_00 (00:15):
Yes.
Undead.
And I do not mean that as ametaphor.
I was digging through the stackof research for today's deep
dive, and scientific literatureactually calls them zombie
cells.
SPEAKER_02 (00:25):
Well, it is a very catchy phrase.
SPEAKER_00 (00:27):
Dude, they are damaged, they absolutely refuse
to die, and they are justactively rusting your healthy
tissues from the inside out.
SPEAKER_02 (00:34):
It is a striking image, I'll give you that.
And while, you know, zombiecells is the colloquial term
that gets thrown around a lot inpopular science, it is actually
entirely accurate to theunderlying biology.
The clinical term is cellularsenescence, and it's honestly,
it's arguably the most criticalfrontier in geroscience right
now.
SPEAKER_00 (00:52):
And that is exactly what we are unpacking today.
Welcome to the deep dive.
We've got an immense stack ofsources to get through today.
I mean, we are looking atcutting-edge clinical trial data
from the Mayo Clinic, uh,biotech pipeline reports from
companies like UnityBiotechnology and Rubido Life
Sciences looking into 2026, andsome incredibly dense cellular
(01:15):
biology breakdowns.
SPEAKER_02 (01:16):
Aaron Powell Very dense.
The landscape of this researchhas shifted dramatically, even
in just the last, say, fewyears.
We've moved from theoreticalmodels in mice to human clinical
trials with highly specificpharmacological targets.
SPEAKER_00 (01:29):
Aaron Powell Right.
And that brings up the missionfor today.
Because if you spend like fiveminutes on the internet looking
up anti-aging or longevity, youare gonna get hit with just a
tidal wave of hype.
SPEAKER_02 (01:39):
Oh, absolutely.
The internet is flooded with thecolour.
SPEAKER_00 (01:41):
People selling you supposed miracle supplements,
biohackers claiming they'regonna live to 150.
So we are cutting through all ofthat.
We're gonna look at the actualproven science of Cynoletics.
Aaron Powell, Jr.
SPEAKER_02 (01:51):
Which is much more complicated than a miracle pill.
SPEAKER_00 (01:53):
Exactly.
We're gonna figure out whatthese zombie cells are actually
doing, how the drugs designed tokill them operate on a molecular
level, and what clearing themout really means for human
disease.
Because, spoiler alert, it isnot a magic anti-aging
multivitamin.
SPEAKER_02 (02:08):
Aaron Powell Far from it.
I mean, the biology ofsemescence is highly nuanced.
It's a protective mechanism thatgoes profoundly wrong over time.
Aaron Powell Okay.
SPEAKER_00 (02:16):
Well, let's start right there.
Yeah.
Because before we get into thedrugs that assassinate these
things, we have to understandthe target.
I was stuck on this whilereading the initial biology
breakdown.
SPEAKER_02 (02:24):
Aaron Powell Okay, where did you get stuck?
SPEAKER_00 (02:25):
Aaron Powell So a cell is taking on damage, right?
Let's say from UV radiation oruh oxidative stress.
Normal biological wear and tear.
SPEAKER_02 (02:34):
Right.
SPEAKER_00 (02:34):
Usually if a cell gets too damaged, it just it
dies.
It takes one for the team.
SPEAKER_02 (02:38):
Yes, the process of apoptosis.
Programmed cell death.
Under normal circumstances, if acell experiences a critical
level of stress, say severe DNAdouble strand breaks, or on
K-gene activation.
Wait, on K-gene activation,that's that's a mutation that
could lead to unchecked divisionin cancer.
So the cell senses that damage.
It triggers a highly regulatedcascade of enzymes called
(03:01):
caspases that systematicallydismantle the cell from the
inside.
SPEAKER_00 (03:05):
Like a controlled demolition.
SPEAKER_02 (03:07):
Exactly like that.
It neatly packages itself up tobe consumed by the immune
system.
SPEAKER_00 (03:12):
It's polite.
It cleans up after itself so itdoesn't become a tumor.
But a zombie cell doesn't dothat.
It pulls an emergency breakinstead.
SPEAKER_02 (03:19):
Correct.
Because sometimes the damage issignificant enough to be
dangerous, but perhaps notcatastrophic enough to trigger
immediate apoptosis.
Or occasionally, the cell'sapoptotic machinery is somehow
compromised.
SPEAKER_00 (03:32):
So it just stops.
SPEAKER_02 (03:33):
Yes.
Instead of dying, the cellenters a state of permanent cell
cycle arrest.
The key word being permanent, itwill never divide again.
Wow.
This is mediated by tumorsuppressor proteins, primarily
the P16 and P21 pathways, whichphysically block the cell from
replicating its DNA.
SPEAKER_00 (03:49):
I mean, that sounds like a good thing initially.
Like, say you have a car on thehighway, the brakes are out, the
steering is shot, so instead ofdriving it into a crowd and
causing a massive pileup, whichwould be cancer in this
situation, you just slam it intopark.
SPEAKER_02 (04:02):
That's a good analogy.
SPEAKER_00 (04:03):
You leave the engine running, it's just sputtering on
the side of the road, but it'snot moving, it's a fail-safe.
SPEAKER_02 (04:08):
It is an evolutionary master stroke.
Senescence is primarily a potenttumor suppressive mechanism.
I mean, without it, theincidence of cancer in mammals
would be astronomically hunger.
SPEAKER_00 (04:20):
But here's where I get confused.
The car is parked, it's safe.
Why does the immune system justleave it there?
Like you have immune cellsspecifically designed to clear
out garbage, right?
SPEAKER_02 (04:31):
Yes.
Macrophages, natural killercells.
SPEAKER_00 (04:33):
Right.
So why don't they just tow thebroken car to the junkyard?
SPEAKER_02 (04:36):
Because the senescent cell is actively
fighting off the tow truck.
SPEAKER_00 (04:39):
No way.
Really?
SPEAKER_02 (04:40):
Yes.
This is the hallmark of a zombiecell apoptosis resistance.
These cells upregulate networksof anti-apoptotic proteins, most
notably the DCL2 family.
SPEAKER_00 (04:51):
The BCL2 family.
SPEAKER_02 (04:52):
Yeah.
Yes.
That includes BCL2, BCL XL, andBCLW.
SPEAKER_00 (04:57):
Okay, what are those doing?
Because the literature keptreferring to them as survival
networks.
But how does a protein networkstop a cell from dying?
SPEAKER_02 (05:06):
Well, you have to look at the mitochondria, the
energy centers of the cell.
Apoptosis is normally triggeredwhen the mitochondria puncture
their own outer membranes.
SPEAKER_00 (05:14):
Puncture their own membranes.
SPEAKER_02 (05:15):
Yes.
And they release a proteincalled cytochrome C into the
cellular fluid.
That release is essentially thepoint of no return for cell
death.
Now, there are executionerproteins, specifically BX and
BA, that form those pores in themitochondrial membrane.
SPEAKER_00 (05:31):
So BX and B are the demolition crew.
SPEAKER_02 (05:34):
Precisely.
What the BCL2 family proteins dois bind to BX and B egg and
sequester them.
SPEAKER_00 (05:40):
They trap them.
SPEAKER_02 (05:40):
Yes.
They physically trap thedemolition crew so they can't
puncture the mitochondria.
The zombie cell overproducesthese BCL2 proteins, effectively
creating a molecular shield.
SPEAKER_00 (05:51):
That is insane.
SPEAKER_02 (05:52):
The body is sending pro-death signals, the immune
system is trying to induceapoptosis, but the mitochondria
are locked down tight, so thecell survives indefinitely.
SPEAKER_00 (06:00):
That is wild.
It hijacks its own machinery tobuild a bunker.
But it doesn't just sit in thebunker quietly.
SPEAKER_01 (06:06):
No, it certainly does not.
SPEAKER_00 (06:07):
Because if it just sat there, we wouldn't care.
Right.
A few parked cars on the side ofthe highway isn't a big deal.
But it's what they secrete thatcauses the real problem.
The SASP.
SPEAKER_02 (06:20):
Ah, yes.
The senesce associated secretoryphenotype.
This is where the biologicalhorror, as you put it, really
begins.
SPEAKER_00 (06:29):
Right, because the broken car isn't just idling,
it's spewing out this toxicsludge onto all the other cars
driving by.
The sources list all thesethings pro-inflammatory
cytokines, chemokines, matrixmetalloproteines.
It's quite a cocktail.
Yeah.
Break that down for me becausewhat is that cocktail actually
doing to the tissue around it?
SPEAKER_02 (06:47):
Aaron Powell Let's start with the matrix
metalloproteinase or MMPs.
Your cells don't just float in avoid, right?
They are embedded in theextracellular matrix.
SPEAKER_00 (06:55):
The scaffolding.
SPEAKER_02 (06:56):
Exactly.
A structural scaffolding made ofcollagen, elastin, and other
proteins.
MMPs are enzymes that literallychew up and degrade that
scaffolding.
SPEAKER_00 (07:04):
Oh wow, so it's melting the floorboards.
SPEAKER_02 (07:06):
Quite literally.
Then you have the cytokines,like interleukin 6 and
interleukin 1 beta.
These are potent inflammatorysignaling molecules.
Now, in a healthy scenario, sayyou get a deep cut, a few cells
in that wound enter senescence.
They secrete this SASP cocktailtemporarily.
SPEAKER_00 (07:25):
Temporarily being the key word.
SPEAKER_02 (07:26):
Yes.
The cytokines act as a chemicalsiren, calling immune cells to
the area to clear the debris,and the MMPs help break down the
damaged tissue so new tissue canbe laid down.
It's actually a vital part ofwound healing.
SPEAKER_00 (07:39):
Okay, so a temporary alarm is good.
It brings the paramedics.
SPEAKER_02 (07:42):
Yes.
But imagine the alarm neverturns off and the paramedics
stop responding.
As we age, our immune systemundergoes immunosinescence.
It gets sluggish and lessefficient at recognizing and
clearing these zombie cells.
So the senescent cellsaccumulate.
SPEAKER_00 (07:56):
They just build up.
SPEAKER_02 (07:57):
They do.
They set up permanent residencein your joints, your blood
vessels, your adipose tissue,and they just constantly pump
out this toxic SASP.
SPEAKER_00 (08:06):
And that causes what the literature calls
inflammaging.
SPEAKER_02 (08:09):
Exactly.
Chronic, sterile, low-gradeinflammation.
This is arguably the primarydriver of most major age-related
diseases.
SPEAKER_00 (08:18):
Really?
Like what?
SPEAKER_02 (08:19):
Well, if you have senescent chondrocytes in your
knee, the constant release ofMMPs degrades the collagen in
your cartilage, leading directlyto osteoarthritis.
In your blood vessels, senescentendothelial cells secrete
cytokines that cause the vesselwalls to stiffen and accumulate
plaque, driving atherosclerosis.
SPEAKER_00 (08:39):
Dude, so the joint ache you feel when you get out
of bed in your 60s, that's notjust wear and tear.
That's actively beingorchestrated by these zombie
cells spitting poison into yourknee.
SPEAKER_02 (08:49):
Wear and tear causes the initial damage, but the
senescent cells sustain andamplify the degradation.
And there's a peracrine effectthat makes us even more
insidious.
SPEAKER_00 (08:57):
Peracrine meaning how they affect their neighbors.
Because the sources mention thatthis SAP stuff can actually
infect healthy cells.
SPEAKER_02 (09:04):
That's right.
The cytokines secreted by thezombie cell bind to receptors on
the surfaces of adjacentperfectly healthy cells.
This triggers a signalingcascade inside those healthy
cells, often involving reactiveoxygen species or the NF kappa B
pathway that causes the healthycell to experience severe
stress.
And then under that intensestress, the healthy cell pulls
(09:26):
its own emergency brake.
It becomes senescent.
SPEAKER_00 (09:29):
Wait, so it is contagious?
SPEAKER_02 (09:31):
In a biological sense, yes.
The presence of a few senescentcells can trigger a localized
cascade, turning surroundingtissue into a senescent
environment.
It's a vicious, self-amplifyingcycle of decay.
SPEAKER_00 (09:43):
Okay, so my knees are full of undead, shielded
cells that are melting thecartilage and biting their
neighbors to make more zombies.
SPEAKER_02 (09:50):
Put colorfully, but yes.
SPEAKER_00 (09:51):
I am starting to see why the geroscience field is so
obsessed with this.
Which brings us to the actualintervention senolytics, the
assassins.
SPEAKER_02 (09:59):
A fitting term for the pharmacology involved.
Yes.
Cenolytics are a class of smallmolecules designed specifically
to selectively induceapoptocious insinescent cells
without harming healthy dividingcells.
SPEAKER_00 (10:10):
And the most famous one in the literature, the
classic combo that started thehuman trials, is D plus Q,
Dacetinib, and Quarcetin.
SPEAKER_02 (10:18):
The pioneers, you could say.
SPEAKER_00 (10:26):
And quircetin is uh onion extract.
SPEAKER_02 (10:30):
It sounds discordant, but the synergy
between them is based on precisecellular targeting.
Senescent cells areheterogeneous.
SPEAKER_00 (10:38):
Meaning they're different depending on where
they are.
SPEAKER_02 (10:40):
Exactly.
A senescent fat cell relies on adifferent survival network than
a senescent blood vessel cell.
Dassatinib is a tyrosine kinaseinhibitor.
It was developed for chronicmyeloid leukemia, but it happens
to powerfully inhibit specifickinase pathways like the SRC
family kinase.
SPEAKER_00 (10:59):
Aaron Powell And what relies on those?
Okay, so the dosatinib takes outthe fat zombies.
But what about the onionextract?
Because the sources from theredox medical group went
incredibly deep into thechemistry of quercetin, and I
want you to walk me through thisbecause it blew my mind.
SPEAKER_01 (11:18):
It is quite elegant.
SPEAKER_00 (11:19):
Because normally we think of flavonoids like
quercetin as antioxidants,right?
Stuff that's good for you,neutralizes free radicals, all
that.
But inside a zombie cell, itacts as a prooxidant.
It literally bombs the cell fromthe inside.
How does that happen?
SPEAKER_02 (11:33):
It's an elegant exploitation of the senescent
cell's own dysfunction.
As cells become senescent andtheir metabolism deranges, they
tend to accumulate highintracellular levels of
transition metals, specificallyredox active pools of copper and
iron.
A healthy cell tightly regulatesthese metals, but a senescent
(11:54):
cell basically hoards them.
SPEAKER_00 (11:55):
It's just full of metallic garbage.
SPEAKER_02 (11:57):
Correct.
Now, quercetin is a redox activeflavonoid.
When it enters a healthy cellthat has normal, low levels of
free iron, it functions as anantioxidant.
Right.
But when quercetin enters thesenescent cell and encounters
this massive hoard of label ironand copper, it triggers what is
known as the fentan reaction.
SPEAKER_00 (12:14):
The fentan reaction.
Okay, what is that doingchemically?
SPEAKER_02 (12:17):
The quercetin essentially donates electrons to
the iron and copper, which thenreact with hydrogen peroxide
naturally present in the cell.
This reaction violently stripsapart the hydrogen peroxide
molecules, creating hydroxylradicals.
SPEAKER_00 (12:30):
Which are bad.
SPEAKER_02 (12:31):
Hydroxyl radicals are arguably the most
destructive reactive oxygenspecies in biology.
They tear through lipids,proteins, and DNA
indiscriminately.
SPEAKER_00 (12:40):
So it's like the cell is a room filled with
gasoline, the iron and copper,and the quercetin is a lit
match.
SPEAKER_02 (12:47):
That's a highly effective way to visualize it.
The resulting explosion ofoxidative stress is so massive,
so immediate, that it completelyoverwhelms the senescent cell's
BCL2 molecular shields.
The mitochondria collapse, theexecutioner caspises are
unleashed, and the zombie cellfinally, irrevocably, undergoes
apoptosis.
SPEAKER_00 (13:08):
Dude, that is just it's biological judo.
You're using the cell's ownhoarded garbage against it to
bypass the shield.
SPEAKER_02 (13:14):
Precisely.
SPEAKER_00 (13:14):
And because healthy cells don't hoard those metals,
the quorsetin just acts like anormal antioxidant in the
surrounding tissue.
There's no collateral damage.
SPEAKER_02 (13:21):
Exactly.
That's why the docetinibinquercetinin combination is so
potent.
You're hitting multiple survivalpathways across different tissue
types simultaneously, clearing abroad spectrum of senescent
cells.
SPEAKER_00 (13:33):
So if quircetin is doing all this damage through
the fentan reaction, what aboutfeesatin?
Because this was all over thelongevity biotech reports.
Feezatin is the next bigsynolytic.
SPEAKER_02 (13:44):
Yes, feezitin is currently a major focus.
SPEAKER_00 (13:47):
And of course, every blog online says strawberries
cure aging because feesatin isin strawberries.
SPEAKER_02 (13:53):
Right.
Let's temper those expectations.
Feezatin is structurally verysimilar to quercetin.
It's also a slavonoid, butpreclinical data suggests it is
an even more potent synolytic incertain cell types.
SPEAKER_01 (14:06):
In fact, work.
SPEAKER_02 (14:07):
Particularly in reducing senescence markers in
the brain and immune system.
It inhibits the BCL2 familydirectly and also drives massive
oxidative stress in thesenescent cells.
SPEAKER_00 (14:16):
But I'm guessing I can't just eat a giant bowl of
strawberries every morning tolive forever.
SPEAKER_02 (14:20):
No, you cannot.
This is where we have toseparate internet biohacking
from pharmacology.
The amount of physicin requiredto achieve a senolytic effect in
human tissue is pharmacologic,not dietary.
For instance, in the AffirmLight Phase II clinical trial,
the dosing protocol is 20milligrams per kilogram of body
weight for two consecutive days.
SPEAKER_00 (14:41):
Okay, so for an average adult.
SPEAKER_02 (14:43):
For an 80 kilogram adult, that's 1600 milligrams of
highly purified physicin, youwould have to consume an
impossible volume ofstrawberries, literally pounds
and pounds, to even approachthat.
SPEAKER_00 (14:56):
And even if I did, the body doesn't just absorb it
perfectly.
SPEAKER_02 (14:58):
Right, exactly.
Dietary flavonoids havenotoriously poor oral
bioavailability.
SPEAKER_00 (15:04):
Meaning they don't make it to the bloodstream.
SPEAKER_02 (15:06):
Right.
When you ingest physicinnaturally, your liver
immediately recognizes it as aforeign compound and subjects it
to extensive first-passmetabolism, primarily
glucuronidation, before it evenreaches your systemic
circulation.
SPEAKER_00 (15:18):
So the liver just neutralizes it.
SPEAKER_02 (15:19):
Pretty much.
The physicin supplements used inthese clinical trials often
require specialized deliverymatrices like liposomes or
phytosome formulations toprotect the molecule from the
liver and ensure it actuallyreaches the target tissues.
SPEAKER_00 (15:31):
Okay, so the smoothie biohackers are out of
luck.
But you just mentioned somethingabout the dosing protocol that
completely tripped me up when Iread the trials.
You said two consecutive days.
SPEAKER_02 (15:42):
Yes, the hit-and-run strategy.
SPEAKER_00 (15:44):
Right.
Because normally if you have achronic condition, you take a
pill every day.
You have high blood pressure,you take an ACE inhibitor daily,
high cholesterol, you take astatin daily.
SPEAKER_01 (15:53):
Standard maintenance dosing, yes.
SPEAKER_00 (15:54):
But with synolytics, you take a massive dose for two
or three days and then you juststop.
For weeks, sometimes months.
Why?
If these cells are so bad,wouldn't I want to be killing
them every single day?
SPEAKER_02 (16:08):
If you take potent senotherapeutics continuously,
you will likely causecatastrophic damage to your own
body.
Wait, really?
Catastrophic?
Yes.
You have to remember what thesedrugs are doing.
They are inhibiting fundamentalcellular survival pathways.
The BCL2 and BCLXL proteinsaren't exclusively used by
zombie cells.
(16:28):
They are critical for thesurvival of many of your
healthy, highly proliferativecells.
SPEAKER_00 (16:33):
Oh, right, because they're just basic biological
mechanisms that the zombieshijacked.
SPEAKER_02 (16:37):
Precisely.
For example, your healthy stemcells, which constantly divide
to repair your tissues, rely onthese networks.
More critically, your bloodplatelets and the megakaryocytes
in your bone marrow that producethem are absolutely dependent on
BCL XL to survive.
SPEAKER_00 (16:53):
So if you block it continuously.
SPEAKER_02 (16:55):
If you suppress that pathway constantly with a daily
pill, you risk severe stem celldepletion and thrombocytopenia,
which is a dangerous drop inyour blood's ability to clot.
You could literally bleed todeath internally.
SPEAKER_00 (17:06):
Whoa.
Okay, so daily use is basicallynuking your own biological
infrastructure.
So how does the hit-and-rundosing bypass that?
SPEAKER_02 (17:14):
By exploiting the kinetics of cellular senescence,
zombie cells do not formovernight.
SPEAKER_00 (17:19):
They're slow.
SPEAKER_02 (17:20):
Very slow.
It takes a significant amount oftime, weeks or even months of
chronic stress and accumulateddamage for a tissue to build up
a high burden of senescentcells.
So you execute a senolyticpulse, you administer a high
dose of deep plus q or physicinfor two or three days.
The drugs reach a peakconcentration in the plasma,
they trigger the phentumreaction or inhibit the kinases,
(17:41):
the vulnerable senescent cellsare pushed into apoptosis, and
then the drugs are rapidlymetabolized and cleared from
your system, usually within 24to 48 hours.
SPEAKER_00 (17:50):
The drugs are gone, but the zombies are dead.
SPEAKER_02 (17:53):
Yes.
The apoptotic process plays outover the next few days.
The toxic SASP cocktaildissipates because the source
has been eliminated.
And most importantly, becausethe synolytic drug is no longer
in your system, your healthystem cells are perfectly safe.
They recognize that theinflammatory roadblock is gone,
and they begin to safely divideand repopulate the tissue space
(18:14):
vacated by the dead zombiecells.
SPEAKER_00 (18:16):
Oh, that makes so much sense.
SPEAKER_02 (18:17):
You wait a month or two for the burden to slowly
build back up from normal livingand then you pulse again.
SPEAKER_00 (18:22):
It's like doing a controlled burn in a forest.
You go in, you burn out all thedead, dry brush so it doesn't
cause a massive wildfire, butyou don't leave the fire burning
all year round.
You get the fire out so the newhealthy trees have room to grow
in the nutrient-rich soil.
SPEAKER_02 (18:38):
That is an excellent way to conceptualize the tissue
regeneration phasepost-clearance.
SPEAKER_00 (18:43):
Okay, so the mechanism makes total sense.
We have the target, the BCL2shields, the fentan reaction
assassins, the hit and rundosing.
But theory is one thing.
I want to know what happens whenyou actually put this into a
living, breathing mammal.
SPEAKER_02 (18:56):
A clinical reality.
SPEAKER_00 (18:58):
Yeah, because the 2026 data we have from the Mayo
Clinic, I mean the murine modelswere insane.
Let's look at the diabetickidney disease study in mice.
SPEAKER_02 (19:06):
Diabetic kidney disease, or DKD, is an ideal
pathology to test senolitics.
SPEAKER_00 (19:11):
Why is that?
SPEAKER_02 (19:12):
The kidney is highly susceptible to senescence.
The chronic high blood glucosein diabetes creates advanced
glycation end products andmassive oxidative stress, which
accelerates senescencespecifically in the renal
proximal tubules.
SPEAKER_00 (19:26):
Right.
And it just creates a ton ofinflammation and scarring
fibrosis that eventually shutsthe kidney down.
SPEAKER_01 (19:30):
Exactly.
SPEAKER_00 (19:31):
So the researchers took these diabetic mice and
they gave them a five-day pulseof the D plus Q combo, oral
gavage, just five days.
And the readouts, they they sawthe obvious stuff, right?
The abundance of senescent cellsdropped.
Yes.
The kidney inflammation markersdropped.
SPEAKER_01 (19:46):
Yeah.
SPEAKER_00 (19:47):
But they also saw an actual reduction in the tissue
fibrosis, the scarring reversed.
Yeah.
And then they saw an increase ingeroprotective factors.
Alpha clotho and SR2-in-1.
SPEAKER_02 (19:56):
Yes.
Very significant markers.
SPEAKER_00 (19:58):
Aaron Powell, What exactly are those and why is it
a big deal that they went up?
SPEAKER_02 (20:01):
Well, SR2-in-1 is an NAD-dependent deacetylas.
It's a protein criticallyinvolved in DNA repair,
mitochondrial biogenesis, andregulating metabolic health.
SPEAKER_00 (20:11):
Aaron Powell Okay, so it keeps the cell running
cleanly.
SPEAKER_02 (20:14):
Precisely.
Alpha clotho is a membraneprotein largely produced in the
kidneys that acts as aco-receptor for fibroblast
growth factors, regulatingphosphate, and acting as a
powerful systemic antioxidant.
SPEAKER_00 (20:25):
So they're the good guys.
SPEAKER_02 (20:26):
Both of these proteins naturally decline as we
age, and they plummetdramatically in disease states
like diabetes.
They are essentially theguardians of youthful cellular
function.
SPEAKER_00 (20:37):
And the senolytic pulse brought them back online?
SPEAKER_02 (20:40):
It restored their expression levels significantly,
yes.
But here's the most crucialparadigm-shifting detail of that
entire mouse study.
The D plus Q treatment mitigatedthe kidney disease, reduced the
fibrosis, and restored thesegeroprotective proteins without
altering the mice's bloodglucose levels at all.
SPEAKER_00 (21:00):
Wait, wait, back up really.
I missed that.
So the mice were still fullydiabetic.
SPEAKER_02 (21:04):
Their blood sugar remained pathologically high the
entire time.
The primary metabolic insult wasstill present and active.
SPEAKER_00 (21:11):
That actually makes no sense until you think about
it.
The fire is still burning, theglucose is still thrashing the
system, but the kidney ishealing anyway.
How?
SPEAKER_02 (21:19):
Because it proves that the primary driver of the
tissue destruction isn't justthe high glucose, it's the
senescent cell's reaction to thehigh glucose.
The glucose triggers a few cellsto become senescent.
Those cells start pumping outSASP.
It's the SAP that drives themassive inflammation, the
fibrosis, and the suppression ofCR2N1 and alpha clotho.
(21:40):
By pulsing D plus Q and clearingout the zombie cells, they shut
off the secondary inflammatorycascade.
SPEAKER_00 (21:47):
Wow.
So you can't cure the diabeteswith D plus Q, but you can
basically bulletproof the tissueagainst the damage it causes by
keeping the inflammatorylandscape totally clean.
SPEAKER_02 (21:57):
Exactly.
It separates the chronologicalprogression of the Disease from
the biological decay of thetissue.
SPEAKER_00 (22:02):
Okay, that is wildly promising.
But as we always have to say onthis show, mice lie and monkeys
exaggerate.
SPEAKER_02 (22:08):
A classic phrasing, but true.
SPEAKER_00 (22:10):
Mice are great, but we are not mice.
What happens in humans?
And this brings us to the 2024Mayo Clinic Trial on Healthy
Human Women.
Because this one is, I mean,it's the reality check for the
whole field, isn't it?
SPEAKER_02 (22:22):
It absolutely is.
It is a vital study because itforces us to confront the
limitations of prophylacticpsynolytics.
SPEAKER_00 (22:28):
So break down the setup here.
This was led by Dr.
Sundeep Kosla, phase two,randomized control trial.
They took 60 healthypostmenopausal women and gave
them intermittent pulses ofdisatinib and quercetin for 20
weeks.
SPEAKER_02 (22:41):
Yes.
SPEAKER_00 (22:41):
And they were specifically looking at bone
metabolism.
Why bone?
SPEAKER_02 (22:45):
Because postmenopausal women experience
a sharp decline in circulatingestrogen.
Estrogen normally plays a keyrole in suppressing cellular
senescence in the bonemicroenvironment.
SPEAKER_01 (22:56):
Okay.
SPEAKER_02 (22:57):
So when estrogen drops, senescent cells
accumulate in the bone marrow,secreting SASP that actively
promotes osteoclasts, the cellsthat break down bone and inhibit
osteoblasts, the cells thatbuild new bone.
SPEAKER_00 (23:09):
Which causes osteoporosis.
SPEAKER_02 (23:11):
Exactly.
This is a primary driver ofpostmenopausal osteoporosis.
The hypothesis was that aprophylactic D plus Q pulse
would clear the senesin burdenand improve bone mineral
density.
SPEAKER_00 (23:22):
And when I read the top line results, it sounded
like a win.
The paper says D plus Q,increased bone formation markers
and decreased bone resorption.
But then you get into thesubgroup analysis, the fine
print, and it completely changesthe story.
SPEAKER_02 (23:34):
It does.
What did the subgroup analysisreveal?
SPEAKER_00 (23:37):
It showed that the drug combo only had a
significant benefit in the womenwho already had a demonstrably
high burden of senescent cellsat the start of the trial.
If a woman had low senescencemarkers at baseline, the D plus
Q basically did nothing for herbone density.
SPEAKER_02 (23:53):
Nothing beneficial, correct.
It introduces the concept of thesenescence threshold.
SPEAKER_00 (23:57):
But logically, if these zombie cells are bad,
shouldn't killing even a few ofthem be good?
If I'm a perfectly healthy45-year-old and I have just a
little bit of CSP happening, whywouldn't I want to clear it out
early?
SPEAKER_02 (24:09):
Because pharmacological intervention is
never free.
It always comes with abiological cost.
Right.
Dacinib is a powerful tyrosinekinase inhibitor.
Quaratin at those doses causesmassive oxidative stress.
If you have a low burden ofsenescent cells, the ambient
level of SASP in your tissuesisn't high enough to cause
significant systemicdysfunction.
SPEAKER_00 (24:31):
The noise of the alarm bells is quiet.
SPEAKER_02 (24:33):
Yes.
If you drop a systemic bomb likeD plus Q into that environment,
you are indiscriminatelyexposing your healthy cells to
the toxicity of the drugs forvery little therapeutic payoff.
SPEAKER_00 (24:46):
You're risking off-target effects when there's
no real enemy to fight yet.
SPEAKER_02 (24:49):
Precisely.
You are accepting all theclinical risk for a zero
measurable reward.
Dr.
Kosala's findings arguevehemently against the idea of
systemic synolytics as auniversal anti-aging
preventative.
SPEAKER_00 (25:02):
That makes total sense.
SPEAKER_02 (25:03):
If your biological age is relatively young and your
tissues aren't overrun,intervening with senolytics
could theoretically disruptnormal healthy tissue
homeostasis.
SPEAKER_00 (25:13):
Okay.
So if the perfectly healthypeople shouldn't be taking this,
who are the people with a highbaseline burden?
Who actually has an overrunsystem that needs an airstrike?
SPEAKER_02 (25:21):
Well, beyond the chronologically very old, the
target demographics arepopulations experiencing
accelerated aging.
The most prominent group wouldbe cancer survivors who have
undergone extensive chemotherapyor radiation therapy.
SPEAKER_00 (25:33):
Oh, because the chemo damages the cells.
SPEAKER_02 (25:35):
Immensely.
Doxerubicin, radiation, thesecause massive genotoxic stress.
They induce severe DNA damageacross the whole body.
Right.
To prevent that damage fromturning into secondary cancers,
huge swathes of the patient'scellular population pull the
emergency brake and entersenescence.
SPEAKER_00 (25:53):
So you survive the cancer, but the treatment
effectively force ages your bodyby filling it with zombie cells.
SPEAKER_02 (25:59):
Exactly.
This is why many childhoodcancer survivors suffer from
early onset frailty, prematureosteoporosis, and cardiovascular
disease in their 30s and 40s.
Their senescent burden isartificially and pathologically
high.
SPEAKER_00 (26:13):
And for them, clearing it out would be
life-changing.
SPEAKER_02 (26:15):
For that population, a synolytic protocol could be
utterly transformative.
Other groups include individualswith chronic viral infections
like HIV, severe metabolicsyndrome, or progeroid
syndromes, which are geneticdiseases that cause rapid aging.
SPEAKER_00 (26:29):
Right.
But for a healthy guy, buyingunregulated physetin capsules
off the internet.
SPEAKER_02 (26:33):
It is a waste of money and potentially a risk to
their health.
SPEAKER_00 (26:36):
Man, that is a tough pill to swallow for the
biohacker community, whichperfectly transitions us to the
state of the longevity biotechpipeline in 2026.
Because if systemic whole bodyanti-aging isn't working the way
we hoped, where's the moneyactually going?
SPEAKER_01 (26:49):
The field has had to pivot.
SPEAKER_00 (26:50):
Right.
And the longevity next report wereviewed was pretty stark about
this.
SPEAKER_02 (26:54):
It was a very sobering analysis.
The field has matured rapidly,and with that maturity comes the
realization that broad systemicclearance of senescent cells in
humans is fraught withcomplexities we haven't fully
solved yet.
SPEAKER_00 (27:08):
And the prime example of this was the massive
failure of UBX01 as a one.
This one hurt to read.
SPEAKER_02 (27:14):
It was a significant setback for Unity biotechnology,
yes.
SPEAKER_00 (27:17):
Aaron Powell They developed this drug specifically
for knee osteoarthritis, which,based on everything we just
talked about with cartilage andMMPs melting the floorboards,
sounds like the most logical,perfect target in the world.
You inject the senolytic rightinto the arthritic knee, it
kills the zombies, the SACTstops.
SPEAKER_01 (27:33):
That was the hypothesis.
SPEAKER_00 (27:35):
But it failed phase two clinical trials.
It couldn't beat a placebo forpain severity.
Why?
If the biology is so sound, whydid the clinical trial fail?
SPEAKER_02 (27:45):
Aaron Powell It is a profound lesson in the
difference between haltingtissue destruction and achieving
tissue regeneration.
We have to look at the anatomyof articular cartilage.
Okay.
Cartilage is in a vasculartissue, it does not have a
direct blood supply.
The chondrocytes, the cells thatmaintain the cartilage are
sparsely distributed and lockedwithin a dense collagen matrix.
SPEAKER_00 (28:05):
Aaron Powell Right.
They're like little islandssuspended in the gel.
SPEAKER_02 (28:08):
Yes.
Now, as osteoarthritisprogresses, the senescent
chondrocytes secrete MMPs thatirrevocably degrade that
collagen network.
By the time a patient isexperiencing severe chronic pain
and qualifies for a clinicaltrial, the structural
architecture of the knee jointis already devastated.
SPEAKER_00 (28:23):
Aaron Powell The floorboards are completely
rotted through.
SPEAKER_02 (28:26):
Precisely.
So Unity injects UBX01001.
The drug effectively clears thesenescent chondrocytes, the
localized SAC drops, the activechemical degradation stops.
SPEAKER_00 (28:37):
So it worked.
SPEAKER_02 (28:37):
Wait.
But and this is the criticalfailure point.
Clearing the senescent cellsdoes not magically regrow the
destroyed cartilage.
Because cartilage lacks a bloodsupply and a robust population
of stem cells, its regenerativecapacity is incredibly low.
SPEAKER_00 (28:53):
I get it.
You put out the fire in thehouse, but the house is still
burned down.
SPEAKER_02 (28:57):
Exactly.
SPEAKER_00 (28:57):
Putting out the fire doesn't rebuild the walls.
The patient is still walking onbone-on-bone friction.
SPEAKER_02 (29:02):
Exactly.
The senolytic achieved itsbiological endpoint.
It cleared the cells, but itfailed its clinical endpoint
because the tissue could notheal the structural deficit.
That's brutal.
The lesson here isn't thatsynolytics don't work, it's that
synolytics are not inherentlyregenerative medicine.
They prepare the biological soilby removing the toxic weeds, but
(29:23):
they do not plant the new seeds.
For tissues with poorregenerative capacity, clearing
the senescent cells late in thedisease process isn't enough to
reverse the pathology.
SPEAKER_00 (29:33):
That is just biology is so unforgiving.
So if systemic pills are toorisky for healthy people and
injecting worn-out jointsdoesn't rebuild the cartilage,
where is the actual successhappening right now?
SPEAKER_02 (29:44):
The successes are entirely found in precision,
localized applications intissues that do have
regenerative capacity, or wherehalting the inflammation
immediately restores function.
SPEAKER_01 (29:54):
Like where?
SPEAKER_02 (29:55):
Well, ironically, Unity Biotechnology provided the
perfect counterexample to theirarthritis failure with a
different drug, UBXREN325.
SPEAKER_00 (30:03):
Yes.
The eye injections.
I was reading the Behold andAspire study data on this, and
it's fascinating.
They targeted diabetic macularedema or DME.
Break down the pathology of DMEreally quickly so we understand
the target.
SPEAKER_02 (30:16):
In diabetic macular edema, the chronic high blood
glucose damages the delicateendothelial cells lining the
capillaries in the retina.
SPEAKER_01 (30:23):
Okay.
SPEAKER_02 (30:24):
This damage leads to hypoxia lack of oxygen.
The tissue responds byupregulating vascular
endothelial growth factor, orVEGF, trying to grow new blood
vessels.
But the environment is highlyinflamed and those endothelial
cells become senescent.
SPEAKER_00 (30:38):
So they pump out SASP.
SPEAKER_02 (30:39):
Yes.
They secrete SASP, which causesthe blood vessels to become
hyperpermeable.
They literally leak fluid andlipids into the macula, causing
swelling and severe vision loss.
SPEAKER_00 (30:50):
Okay, so the retina is swollen with leaky fluid
because of the zombie bloodvessels.
So Unity takes UBX1325, which isa BCL XL inhibitor.
It specifically blocks thatanti-apoptotic shield.
SPEAKER_01 (31:03):
Correct.
SPEAKER_00 (31:04):
And instead of giving it as a pill, they inject
it directly into the eyeball.
Intravitrial injection.
SPEAKER_01 (31:09):
A highly sequestered localized delivery mechanism.
SPEAKER_00 (31:13):
And it worked.
The patients actually gainedletters on the standard eye
chart.
Their vision improved and theretinal fluid decreased.
But the part I want to focus onis why they had to inject it
into the eye.
Because it comes back to theNivitoclax problem we danced
around earlier.
SPEAKER_01 (31:27):
Ah, yes.
SPEAKER_00 (31:28):
If BCL XL is the shield, why can't I just take a
BCL XL inhibitor pill to cure myeye?
SPEAKER_02 (31:33):
Because of your blood platelets.
Navidoclax is one of the mostpotent BCL XL inhibitors ever
discovered.
In vitro, it obliteratessenescent cells.
South great.
But as we discussed with thehit-and-run strategy, your
healthy blood platelets areutterly dependent on BCL XL to
survive their normal lifespan incirculation.
SPEAKER_00 (31:50):
The drug can't tell the difference between a zombie
cell shield and a plateletshield.
SPEAKER_02 (31:54):
Exactly.
And the molecule of Nivitoclaxdoesn't know where it is, it
just binds to BCL XL.
If you take Navitoclaxsystemically as an oral pill, it
enters your gastrointestinaltract, goes into your
bloodstream, and immediatelyencounters billions of
platelets.
SPEAKER_01 (32:08):
Oh no.
SPEAKER_02 (32:09):
It inhibits their BCL XL and the platelets undergo
apoptosis.
Before the drug ever reaches thesenescent cells in your retina,
it has caused catastrophicdose-limiting thrombocytopenia.
You would suffer severe internalbleeding.
SPEAKER_00 (32:23):
So the systemic route is a dead end for BCL XL
inhibitors.
But if you bypass thebloodstream entirely.
SPEAKER_02 (32:29):
Exactly.
By injecting UBX 1325 directlyinto the vitreous humor of the
eye, the drug remains localized.
It reaches high concentrationsin the retina, clears the
senescent vascular cells, shutsdown leaky vessels, and allows
the edema to resolve.
SPEAKER_01 (32:43):
That's brilliant.
SPEAKER_02 (32:44):
And because the eye is largely isolated from the
systemic circulation, the drugnever hits the platelets in your
bloodstream.
It is a masterpiece of precisionpharmacology.
SPEAKER_00 (32:53):
A biological sniper rifle.
And they're doing this with skinnow, too, right?
The 2026 biotech pipelinementioned Rubido Life Sciences
and a drug called RLS 1496.
SPEAKER_02 (33:03):
Yes, Rubedo is taking a similarly localized
approach.
RLS 1496 is formulated as atopical treatment, a cream or
ointment targetingdermatological conditions driven
by senescence.
SPEAKER_00 (33:14):
Like what?
SPEAKER_02 (33:15):
Things like chronic plaxoriasis or actinic
keratosis, which is a precursorto skin cancer caused by UV
damage.
SPEAKER_00 (33:23):
So again, you're not taking a pill.
You have a patch of severelydamaged, chronologically aged
skin, and you just apply thesenolytic directly to the
target.
It sinks in, causes the fentanreaction, or inhibits the
kinases locally, kills thezombies, and spares the rest of
your body.
SPEAKER_02 (33:38):
Precisely.
The field has evolved from theblunt force trauma of systemic
anti-aging into highlysophisticated localized
interventions.
Right.
The core science of cellularsenescence remains incredibly
robust.
The mechanisms are proven.
SASP degrades tissue, synolyticscan clear it.
But the translational realityrequires us to be meticulous
about how, when, and where wedeploy these agents.
(34:01):
We need highly specificbiomarkers to identify which
tissues are burdened, and weneed delivery systems that
minimize collateral damage.
SPEAKER_00 (34:08):
Man, it's just incredible to see how fast this
is moving, but also how complexthe reality is compared to the
headlines.
So let's pull all of thistogether for you listening right
now, whose brain is probablyoverflowing with acronyms.
SPEAKER_01 (34:21):
It is a lot of terminology to digest.
SPEAKER_00 (34:23):
We started with this wild sci-fi concept of zombie
cells.
Cells that get damaged, refuseto undergo apoptosis, and pull
the emergency brake, lockingthemselves into permanent cell
cycle arrest.
SPEAKER_02 (34:35):
And they survive by upregulating the BCL2 family of
proteins, creating a molecularshield that traps the
executioner enzymes and preventsthe mitochondria from initiating
cell death.
SPEAKER_00 (34:46):
Right.
And while they sit there,completely indencible, they
start skewing out the SSAP, thetoxic sludge of cytokines and
MMPs that literally melts theextracellular matrix around
them, causes massive chronicinflammation, and even infects
neighboring healthy cells,turning them into zombies too.
SPEAKER_02 (35:01):
Which leads us to the assassins.
Senolytics like dosetinib andquercetin, they bypass the
shields through targeted kinaseinhibition and exploiting the
senescent cells' own hoardedtransition metals.
SPEAKER_00 (35:12):
The fentan reaction.
SPEAKER_02 (35:13):
Yes, using the fentan reaction to generate
massive oxidative stress fromthe inside out.
SPEAKER_00 (35:18):
But because those biological pathways are shared
with healthy stem cells andplatelets, we have to use the
hit-and-run dosing protocol.
Pulse the drug, clear thetissue, let the drug wash out,
and give the healthy cells timeto regenerate the tissue.
SPEAKER_02 (35:31):
And while the preclinical data in murine
models of diabetic kidneydisease showed profound
restoration of geroprotectivefactors like CER2 and 1 without
even fixing the underlyingdiabetes.
SPEAKER_00 (35:42):
The human trials were the reality check.
SPEAKER_02 (35:44):
Yes.
The human clinical trials taughtus that systemic administration
is only beneficial if you have amassive pathological burden of
senescent cells, like a cancersurvivor post-chemotherapy.
SPEAKER_00 (35:55):
Right, leading to the 2026 reality where the big
wins are happening in precisionmedicine.
Eye injections for macularedema, toticle creams for skin
diseases, putting the sniperexactly where the target is.
SPEAKER_02 (36:05):
An incredibly thorough synthesis of a very
complex landscape.
SPEAKER_00 (36:16):
And it's kind of a mind-expanding way to look at
the future of human health.
SPEAKER_02 (36:20):
Oh.
I am curious to hear where yourmind has gone with this.
SPEAKER_00 (36:24):
Aaron Powell Well, we've always viewed aging as
this unstoppable whole-bodysystemic decline, like a tide
going out.
It happens to everything all atonce.
SPEAKER_02 (36:33):
Aaron Ross Powell The traditional view of aging,
yes.
SPEAKER_00 (36:35):
Aaron Powell But if CNLetics continue to evolve
exactly the way Unity and Rubedoare pushing them, these highly
localized, precise tools, maybeaging won't be seen as a
systemic failure anymore.
Maybe getting older will justbecome a series of localized
scheduled maintenanceappointments.
SPEAKER_02 (36:50):
Aaron Powell Hmm.
That shifts the paradigm frominevitable decay to managed
localized wear.
SPEAKER_00 (36:56):
Exactly.
Imagine it.
Imagine walking into aspecialized longevity clinic
when you're 70 years old.
You aren't there for a majorinvasive surgery, and you aren't
there to pick up a magic pillthat keeps you 25 forever.
You're just there to get thezombie cells cleaned out of a
specific area.
You get an injection in yourleft knee, some drops in your
retinas, maybe a topicaltreatment on your sun-damaged
(37:17):
shoulders.
You wait three days for theapoptosis to finish, the
inflammation clears, your stemcells rebuild the microscopic
damage, and you go about yourlife.
SPEAKER_02 (37:26):
Like routine servicing.
SPEAKER_00 (37:28):
It would be the exact same way you go to the
dentist every six months to getplaque scraped off your teeth
before it rots your gums.
Just routine localizedmaintenance.
SPEAKER_02 (37:37):
The conceptualization of senescence
as biological plaque is highlyresonant.
If we can develop the diagnosticimaging to accurately map the
senescent burden in real time,that future is entirely
plausible.
SPEAKER_00 (37:48):
What does human life actually look like when aging
isn't an inevitable full-bodytragedy, but just a routine
maintenance schedule?
Keep the diagnostics running,find the zombies, clear them
out, and go about your day.
SPEAKER_02 (38:00):
It is a profound question, and one the field of
geroscience is actively workingto answer.
SPEAKER_00 (38:05):
And we will be right here tracking it as it happens.
Thank you all so much for divingdeep into the biology of the
undead with us today.
Keep learning, keep questioning,and we'll catch you on the next
deep dive.
So, uh, you're just sitting there right now, maybe
you're driving, or I don't know,maybe you're making coffee.
You feel totally normal.
But inside your tissues, yeah,like literally right this
second, there are undead cells.
SPEAKER_01 (00:14):
Undead.
SPEAKER_00 (00:15):
Yes.
Undead.
And I do not mean that as ametaphor.
I was digging through the stackof research for today's deep
dive, and scientific literatureactually calls them zombie
cells.
SPEAKER_02 (00:25):
Well, it is a very catchy phrase.
SPEAKER_00 (00:27):
Dude, they are damaged, they absolutely refuse
to die, and they are justactively rusting your healthy
tissues from the inside out.
SPEAKER_02 (00:34):
It is a striking image, I'll give you that.
And while, you know, zombiecells is the colloquial term
that gets thrown around a lot inpopular science, it is actually
entirely accurate to theunderlying biology.
The clinical term is cellularsenescence, and it's honestly,
it's arguably the most criticalfrontier in geroscience right
now.
SPEAKER_00 (00:52):
And that is exactly what we are unpacking today.
Welcome to the deep dive.
We've got an immense stack ofsources to get through today.
I mean, we are looking atcutting-edge clinical trial data
from the Mayo Clinic, uh,biotech pipeline reports from
companies like UnityBiotechnology and Rubido Life
Sciences looking into 2026, andsome incredibly dense cellular
(01:15):
biology breakdowns.
SPEAKER_02 (01:16):
Aaron Powell Very dense.
The landscape of this researchhas shifted dramatically, even
in just the last, say, fewyears.
We've moved from theoreticalmodels in mice to human clinical
trials with highly specificpharmacological targets.
SPEAKER_00 (01:29):
Aaron Powell Right.
And that brings up the missionfor today.
Because if you spend like fiveminutes on the internet looking
up anti-aging or longevity, youare gonna get hit with just a
tidal wave of hype.
SPEAKER_02 (01:39):
Oh, absolutely.
The internet is flooded with thecolour.
SPEAKER_00 (01:41):
People selling you supposed miracle supplements,
biohackers claiming they'regonna live to 150.
So we are cutting through all ofthat.
We're gonna look at the actualproven science of Cynoletics.
Aaron Powell, Jr.
SPEAKER_02 (01:51):
Which is much more complicated than a miracle pill.
SPEAKER_00 (01:53):
Exactly.
We're gonna figure out whatthese zombie cells are actually
doing, how the drugs designed tokill them operate on a molecular
level, and what clearing themout really means for human
disease.
Because, spoiler alert, it isnot a magic anti-aging
multivitamin.
SPEAKER_02 (02:08):
Aaron Powell Far from it.
I mean, the biology ofsemescence is highly nuanced.
It's a protective mechanism thatgoes profoundly wrong over time.
Aaron Powell Okay.
SPEAKER_00 (02:16):
Well, let's start right there.
Yeah.
Because before we get into thedrugs that assassinate these
things, we have to understandthe target.
I was stuck on this whilereading the initial biology
breakdown.
SPEAKER_02 (02:24):
Aaron Powell Okay, where did you get stuck?
SPEAKER_00 (02:25):
Aaron Powell So a cell is taking on damage, right?
Let's say from UV radiation oruh oxidative stress.
Normal biological wear and tear.
SPEAKER_02 (02:34):
Right.
SPEAKER_00 (02:34):
Usually if a cell gets too damaged, it just it
dies.
It takes one for the team.
SPEAKER_02 (02:38):
Yes, the process of apoptosis.
Programmed cell death.
Under normal circumstances, if acell experiences a critical
level of stress, say severe DNAdouble strand breaks, or on
K-gene activation.
Wait, on K-gene activation,that's that's a mutation that
could lead to unchecked divisionin cancer.
So the cell senses that damage.
It triggers a highly regulatedcascade of enzymes called
(03:01):
caspases that systematicallydismantle the cell from the
inside.
SPEAKER_00 (03:05):
Like a controlled demolition.
SPEAKER_02 (03:07):
Exactly like that.
It neatly packages itself up tobe consumed by the immune
system.
SPEAKER_00 (03:12):
It's polite.
It cleans up after itself so itdoesn't become a tumor.
But a zombie cell doesn't dothat.
It pulls an emergency breakinstead.
SPEAKER_02 (03:19):
Correct.
Because sometimes the damage issignificant enough to be
dangerous, but perhaps notcatastrophic enough to trigger
immediate apoptosis.
Or occasionally, the cell'sapoptotic machinery is somehow
compromised.
SPEAKER_00 (03:32):
So it just stops.
SPEAKER_02 (03:33):
Yes.
Instead of dying, the cellenters a state of permanent cell
cycle arrest.
The key word being permanent, itwill never divide again.
Wow.
This is mediated by tumorsuppressor proteins, primarily
the P16 and P21 pathways, whichphysically block the cell from
replicating its DNA.
SPEAKER_00 (03:49):
I mean, that sounds like a good thing initially.
Like, say you have a car on thehighway, the brakes are out, the
steering is shot, so instead ofdriving it into a crowd and
causing a massive pileup, whichwould be cancer in this
situation, you just slam it intopark.
SPEAKER_02 (04:02):
That's a good analogy.
SPEAKER_00 (04:03):
You leave the engine running, it's just sputtering on
the side of the road, but it'snot moving, it's a fail-safe.
SPEAKER_02 (04:08):
It is an evolutionary master stroke.
Senescence is primarily a potenttumor suppressive mechanism.
I mean, without it, theincidence of cancer in mammals
would be astronomically hunger.
SPEAKER_00 (04:20):
But here's where I get confused.
The car is parked, it's safe.
Why does the immune system justleave it there?
Like you have immune cellsspecifically designed to clear
out garbage, right?
SPEAKER_02 (04:31):
Yes.
Macrophages, natural killercells.
SPEAKER_00 (04:33):
Right.
So why don't they just tow thebroken car to the junkyard?
SPEAKER_02 (04:36):
Because the senescent cell is actively
fighting off the tow truck.
SPEAKER_00 (04:39):
No way.
Really?
SPEAKER_02 (04:40):
Yes.
This is the hallmark of a zombiecell apoptosis resistance.
These cells upregulate networksof anti-apoptotic proteins, most
notably the DCL2 family.
SPEAKER_00 (04:51):
The BCL2 family.
SPEAKER_02 (04:52):
Yeah.
Yes.
That includes BCL2, BCL XL, andBCLW.
SPEAKER_00 (04:57):
Okay, what are those doing?
Because the literature keptreferring to them as survival
networks.
But how does a protein networkstop a cell from dying?
SPEAKER_02 (05:06):
Well, you have to look at the mitochondria, the
energy centers of the cell.
Apoptosis is normally triggeredwhen the mitochondria puncture
their own outer membranes.
SPEAKER_00 (05:14):
Puncture their own membranes.
SPEAKER_02 (05:15):
Yes.
And they release a proteincalled cytochrome C into the
cellular fluid.
That release is essentially thepoint of no return for cell
death.
Now, there are executionerproteins, specifically BX and
BA, that form those pores in themitochondrial membrane.
SPEAKER_00 (05:31):
So BX and B are the demolition crew.
SPEAKER_02 (05:34):
Precisely.
What the BCL2 family proteins dois bind to BX and B egg and
sequester them.
SPEAKER_00 (05:40):
They trap them.
SPEAKER_02 (05:40):
Yes.
They physically trap thedemolition crew so they can't
puncture the mitochondria.
The zombie cell overproducesthese BCL2 proteins, effectively
creating a molecular shield.
SPEAKER_00 (05:51):
That is insane.
SPEAKER_02 (05:52):
The body is sending pro-death signals, the immune
system is trying to induceapoptosis, but the mitochondria
are locked down tight, so thecell survives indefinitely.
SPEAKER_00 (06:00):
That is wild.
It hijacks its own machinery tobuild a bunker.
But it doesn't just sit in thebunker quietly.
SPEAKER_01 (06:06):
No, it certainly does not.
SPEAKER_00 (06:07):
Because if it just sat there, we wouldn't care.
Right.
A few parked cars on the side ofthe highway isn't a big deal.
But it's what they secrete thatcauses the real problem.
The SASP.
SPEAKER_02 (06:20):
Ah, yes.
The senesce associated secretoryphenotype.
This is where the biologicalhorror, as you put it, really
begins.
SPEAKER_00 (06:29):
Right, because the broken car isn't just idling,
it's spewing out this toxicsludge onto all the other cars
driving by.
The sources list all thesethings pro-inflammatory
cytokines, chemokines, matrixmetalloproteines.
It's quite a cocktail.
Yeah.
Break that down for me becausewhat is that cocktail actually
doing to the tissue around it?
SPEAKER_02 (06:47):
Aaron Powell Let's start with the matrix
metalloproteinase or MMPs.
Your cells don't just float in avoid, right?
They are embedded in theextracellular matrix.
SPEAKER_00 (06:55):
The scaffolding.
SPEAKER_02 (06:56):
Exactly.
A structural scaffolding made ofcollagen, elastin, and other
proteins.
MMPs are enzymes that literallychew up and degrade that
scaffolding.
SPEAKER_00 (07:04):
Oh wow, so it's melting the floorboards.
SPEAKER_02 (07:06):
Quite literally.
Then you have the cytokines,like interleukin 6 and
interleukin 1 beta.
These are potent inflammatorysignaling molecules.
Now, in a healthy scenario, sayyou get a deep cut, a few cells
in that wound enter senescence.
They secrete this SASP cocktailtemporarily.
SPEAKER_00 (07:25):
Temporarily being the key word.
SPEAKER_02 (07:26):
Yes.
The cytokines act as a chemicalsiren, calling immune cells to
the area to clear the debris,and the MMPs help break down the
damaged tissue so new tissue canbe laid down.
It's actually a vital part ofwound healing.
SPEAKER_00 (07:39):
Okay, so a temporary alarm is good.
It brings the paramedics.
SPEAKER_02 (07:42):
Yes.
But imagine the alarm neverturns off and the paramedics
stop responding.
As we age, our immune systemundergoes immunosinescence.
It gets sluggish and lessefficient at recognizing and
clearing these zombie cells.
So the senescent cellsaccumulate.
SPEAKER_00 (07:56):
They just build up.
SPEAKER_02 (07:57):
They do.
They set up permanent residencein your joints, your blood
vessels, your adipose tissue,and they just constantly pump
out this toxic SASP.
SPEAKER_00 (08:06):
And that causes what the literature calls
inflammaging.
SPEAKER_02 (08:09):
Exactly.
Chronic, sterile, low-gradeinflammation.
This is arguably the primarydriver of most major age-related
diseases.
SPEAKER_00 (08:18):
Really?
Like what?
SPEAKER_02 (08:19):
Well, if you have senescent chondrocytes in your
knee, the constant release ofMMPs degrades the collagen in
your cartilage, leading directlyto osteoarthritis.
In your blood vessels, senescentendothelial cells secrete
cytokines that cause the vesselwalls to stiffen and accumulate
plaque, driving atherosclerosis.
SPEAKER_00 (08:39):
Dude, so the joint ache you feel when you get out
of bed in your 60s, that's notjust wear and tear.
That's actively beingorchestrated by these zombie
cells spitting poison into yourknee.
SPEAKER_02 (08:49):
Wear and tear causes the initial damage, but the
senescent cells sustain andamplify the degradation.
And there's a peracrine effectthat makes us even more
insidious.
SPEAKER_00 (08:57):
Peracrine meaning how they affect their neighbors.
Because the sources mention thatthis SAP stuff can actually
infect healthy cells.
SPEAKER_02 (09:04):
That's right.
The cytokines secreted by thezombie cell bind to receptors on
the surfaces of adjacentperfectly healthy cells.
This triggers a signalingcascade inside those healthy
cells, often involving reactiveoxygen species or the NF kappa B
pathway that causes the healthycell to experience severe
stress.
And then under that intensestress, the healthy cell pulls
(09:26):
its own emergency brake.
It becomes senescent.
SPEAKER_00 (09:29):
Wait, so it is contagious?
SPEAKER_02 (09:31):
In a biological sense, yes.
The presence of a few senescentcells can trigger a localized
cascade, turning surroundingtissue into a senescent
environment.
It's a vicious, self-amplifyingcycle of decay.
SPEAKER_00 (09:43):
Okay, so my knees are full of undead, shielded
cells that are melting thecartilage and biting their
neighbors to make more zombies.
SPEAKER_02 (09:50):
Put colorfully, but yes.
SPEAKER_00 (09:51):
I am starting to see why the geroscience field is so
obsessed with this.
Which brings us to the actualintervention senolytics, the
assassins.
SPEAKER_02 (09:59):
A fitting term for the pharmacology involved.
Yes.
Cenolytics are a class of smallmolecules designed specifically
to selectively induceapoptocious insinescent cells
without harming healthy dividingcells.
SPEAKER_00 (10:10):
And the most famous one in the literature, the
classic combo that started thehuman trials, is D plus Q,
Dacetinib, and Quarcetin.
SPEAKER_02 (10:18):
The pioneers, you could say.
SPEAKER_00 (10:26):
And quircetin is uh onion extract.
SPEAKER_02 (10:30):
It sounds discordant, but the synergy
between them is based on precisecellular targeting.
Senescent cells areheterogeneous.
SPEAKER_00 (10:38):
Meaning they're different depending on where
they are.
SPEAKER_02 (10:40):
Exactly.
A senescent fat cell relies on adifferent survival network than
a senescent blood vessel cell.
Dassatinib is a tyrosine kinaseinhibitor.
It was developed for chronicmyeloid leukemia, but it happens
to powerfully inhibit specifickinase pathways like the SRC
family kinase.
SPEAKER_00 (10:59):
Aaron Powell And what relies on those?
Okay, so the dosatinib takes outthe fat zombies.
But what about the onionextract?
Because the sources from theredox medical group went
incredibly deep into thechemistry of quercetin, and I
want you to walk me through thisbecause it blew my mind.
SPEAKER_01 (11:18):
It is quite elegant.
SPEAKER_00 (11:19):
Because normally we think of flavonoids like
quercetin as antioxidants,right?
Stuff that's good for you,neutralizes free radicals, all
that.
But inside a zombie cell, itacts as a prooxidant.
It literally bombs the cell fromthe inside.
How does that happen?
SPEAKER_02 (11:33):
It's an elegant exploitation of the senescent
cell's own dysfunction.
As cells become senescent andtheir metabolism deranges, they
tend to accumulate highintracellular levels of
transition metals, specificallyredox active pools of copper and
iron.
A healthy cell tightly regulatesthese metals, but a senescent
(11:54):
cell basically hoards them.
SPEAKER_00 (11:55):
It's just full of metallic garbage.
SPEAKER_02 (11:57):
Correct.
Now, quercetin is a redox activeflavonoid.
When it enters a healthy cellthat has normal, low levels of
free iron, it functions as anantioxidant.
Right.
But when quercetin enters thesenescent cell and encounters
this massive hoard of label ironand copper, it triggers what is
known as the fentan reaction.
SPEAKER_00 (12:14):
The fentan reaction.
Okay, what is that doingchemically?
SPEAKER_02 (12:17):
The quercetin essentially donates electrons to
the iron and copper, which thenreact with hydrogen peroxide
naturally present in the cell.
This reaction violently stripsapart the hydrogen peroxide
molecules, creating hydroxylradicals.
SPEAKER_00 (12:30):
Which are bad.
SPEAKER_02 (12:31):
Hydroxyl radicals are arguably the most
destructive reactive oxygenspecies in biology.
They tear through lipids,proteins, and DNA
indiscriminately.
SPEAKER_00 (12:40):
So it's like the cell is a room filled with
gasoline, the iron and copper,and the quercetin is a lit
match.
SPEAKER_02 (12:47):
That's a highly effective way to visualize it.
The resulting explosion ofoxidative stress is so massive,
so immediate, that it completelyoverwhelms the senescent cell's
BCL2 molecular shields.
The mitochondria collapse, theexecutioner caspises are
unleashed, and the zombie cellfinally, irrevocably, undergoes
apoptosis.
SPEAKER_00 (13:08):
Dude, that is just it's biological judo.
You're using the cell's ownhoarded garbage against it to
bypass the shield.
SPEAKER_02 (13:14):
Precisely.
SPEAKER_00 (13:14):
And because healthy cells don't hoard those metals,
the quorsetin just acts like anormal antioxidant in the
surrounding tissue.
There's no collateral damage.
SPEAKER_02 (13:21):
Exactly.
That's why the docetinibinquercetinin combination is so
potent.
You're hitting multiple survivalpathways across different tissue
types simultaneously, clearing abroad spectrum of senescent
cells.
SPEAKER_00 (13:33):
So if quircetin is doing all this damage through
the fentan reaction, what aboutfeesatin?
Because this was all over thelongevity biotech reports.
Feezatin is the next bigsynolytic.
SPEAKER_02 (13:44):
Yes, feezitin is currently a major focus.
SPEAKER_00 (13:47):
And of course, every blog online says strawberries
cure aging because feesatin isin strawberries.
SPEAKER_02 (13:53):
Right.
Let's temper those expectations.
Feezatin is structurally verysimilar to quercetin.
It's also a slavonoid, butpreclinical data suggests it is
an even more potent synolytic incertain cell types.
SPEAKER_01 (14:06):
In fact, work.
SPEAKER_02 (14:07):
Particularly in reducing senescence markers in
the brain and immune system.
It inhibits the BCL2 familydirectly and also drives massive
oxidative stress in thesenescent cells.
SPEAKER_00 (14:16):
But I'm guessing I can't just eat a giant bowl of
strawberries every morning tolive forever.
SPEAKER_02 (14:20):
No, you cannot.
This is where we have toseparate internet biohacking
from pharmacology.
The amount of physicin requiredto achieve a senolytic effect in
human tissue is pharmacologic,not dietary.
For instance, in the AffirmLight Phase II clinical trial,
the dosing protocol is 20milligrams per kilogram of body
weight for two consecutive days.
SPEAKER_00 (14:41):
Okay, so for an average adult.
SPEAKER_02 (14:43):
For an 80 kilogram adult, that's 1600 milligrams of
highly purified physicin, youwould have to consume an
impossible volume ofstrawberries, literally pounds
and pounds, to even approachthat.
SPEAKER_00 (14:56):
And even if I did, the body doesn't just absorb it
perfectly.
SPEAKER_02 (14:58):
Right, exactly.
Dietary flavonoids havenotoriously poor oral
bioavailability.
SPEAKER_00 (15:04):
Meaning they don't make it to the bloodstream.
SPEAKER_02 (15:06):
Right.
When you ingest physicinnaturally, your liver
immediately recognizes it as aforeign compound and subjects it
to extensive first-passmetabolism, primarily
glucuronidation, before it evenreaches your systemic
circulation.
SPEAKER_00 (15:18):
So the liver just neutralizes it.
SPEAKER_02 (15:19):
Pretty much.
The physicin supplements used inthese clinical trials often
require specialized deliverymatrices like liposomes or
phytosome formulations toprotect the molecule from the
liver and ensure it actuallyreaches the target tissues.
SPEAKER_00 (15:31):
Okay, so the smoothie biohackers are out of
luck.
But you just mentioned somethingabout the dosing protocol that
completely tripped me up when Iread the trials.
You said two consecutive days.
SPEAKER_02 (15:42):
Yes, the hit-and-run strategy.
SPEAKER_00 (15:44):
Right.
Because normally if you have achronic condition, you take a
pill every day.
You have high blood pressure,you take an ACE inhibitor daily,
high cholesterol, you take astatin daily.
SPEAKER_01 (15:53):
Standard maintenance dosing, yes.
SPEAKER_00 (15:54):
But with synolytics, you take a massive dose for two
or three days and then you juststop.
For weeks, sometimes months.
Why?
If these cells are so bad,wouldn't I want to be killing
them every single day?
SPEAKER_02 (16:08):
If you take potent senotherapeutics continuously,
you will likely causecatastrophic damage to your own
body.
Wait, really?
Catastrophic?
Yes.
You have to remember what thesedrugs are doing.
They are inhibiting fundamentalcellular survival pathways.
The BCL2 and BCLXL proteinsaren't exclusively used by
zombie cells.
(16:28):
They are critical for thesurvival of many of your
healthy, highly proliferativecells.
SPEAKER_00 (16:33):
Oh, right, because they're just basic biological
mechanisms that the zombieshijacked.
SPEAKER_02 (16:37):
Precisely.
For example, your healthy stemcells, which constantly divide
to repair your tissues, rely onthese networks.
More critically, your bloodplatelets and the megakaryocytes
in your bone marrow that producethem are absolutely dependent on
BCL XL to survive.
SPEAKER_00 (16:53):
So if you block it continuously.
SPEAKER_02 (16:55):
If you suppress that pathway constantly with a daily
pill, you risk severe stem celldepletion and thrombocytopenia,
which is a dangerous drop inyour blood's ability to clot.
You could literally bleed todeath internally.
SPEAKER_00 (17:06):
Whoa.
Okay, so daily use is basicallynuking your own biological
infrastructure.
So how does the hit-and-rundosing bypass that?
SPEAKER_02 (17:14):
By exploiting the kinetics of cellular senescence,
zombie cells do not formovernight.
SPEAKER_00 (17:19):
They're slow.
SPEAKER_02 (17:20):
Very slow.
It takes a significant amount oftime, weeks or even months of
chronic stress and accumulateddamage for a tissue to build up
a high burden of senescentcells.
So you execute a senolyticpulse, you administer a high
dose of deep plus q or physicinfor two or three days.
The drugs reach a peakconcentration in the plasma,
they trigger the phentumreaction or inhibit the kinases,
(17:41):
the vulnerable senescent cellsare pushed into apoptosis, and
then the drugs are rapidlymetabolized and cleared from
your system, usually within 24to 48 hours.
SPEAKER_00 (17:50):
The drugs are gone, but the zombies are dead.
SPEAKER_02 (17:53):
Yes.
The apoptotic process plays outover the next few days.
The toxic SASP cocktaildissipates because the source
has been eliminated.
And most importantly, becausethe synolytic drug is no longer
in your system, your healthystem cells are perfectly safe.
They recognize that theinflammatory roadblock is gone,
and they begin to safely divideand repopulate the tissue space
(18:14):
vacated by the dead zombiecells.
SPEAKER_00 (18:16):
Oh, that makes so much sense.
SPEAKER_02 (18:17):
You wait a month or two for the burden to slowly
build back up from normal livingand then you pulse again.
SPEAKER_00 (18:22):
It's like doing a controlled burn in a forest.
You go in, you burn out all thedead, dry brush so it doesn't
cause a massive wildfire, butyou don't leave the fire burning
all year round.
You get the fire out so the newhealthy trees have room to grow
in the nutrient-rich soil.
SPEAKER_02 (18:38):
That is an excellent way to conceptualize the tissue
regeneration phasepost-clearance.
SPEAKER_00 (18:43):
Okay, so the mechanism makes total sense.
We have the target, the BCL2shields, the fentan reaction
assassins, the hit and rundosing.
But theory is one thing.
I want to know what happens whenyou actually put this into a
living, breathing mammal.
SPEAKER_02 (18:56):
A clinical reality.
SPEAKER_00 (18:58):
Yeah, because the 2026 data we have from the Mayo
Clinic, I mean the murine modelswere insane.
Let's look at the diabetickidney disease study in mice.
SPEAKER_02 (19:06):
Diabetic kidney disease, or DKD, is an ideal
pathology to test senolitics.
SPEAKER_00 (19:11):
Why is that?
SPEAKER_02 (19:12):
The kidney is highly susceptible to senescence.
The chronic high blood glucosein diabetes creates advanced
glycation end products andmassive oxidative stress, which
accelerates senescencespecifically in the renal
proximal tubules.
SPEAKER_00 (19:26):
Right.
And it just creates a ton ofinflammation and scarring
fibrosis that eventually shutsthe kidney down.
SPEAKER_01 (19:30):
Exactly.
SPEAKER_00 (19:31):
So the researchers took these diabetic mice and
they gave them a five-day pulseof the D plus Q combo, oral
gavage, just five days.
And the readouts, they they sawthe obvious stuff, right?
The abundance of senescent cellsdropped.
Yes.
The kidney inflammation markersdropped.
SPEAKER_01 (19:46):
Yeah.
SPEAKER_00 (19:47):
But they also saw an actual reduction in the tissue
fibrosis, the scarring reversed.
Yeah.
And then they saw an increase ingeroprotective factors.
Alpha clotho and SR2-in-1.
SPEAKER_02 (19:56):
Yes.
Very significant markers.
SPEAKER_00 (19:58):
Aaron Powell, What exactly are those and why is it
a big deal that they went up?
SPEAKER_02 (20:01):
Well, SR2-in-1 is an NAD-dependent deacetylas.
It's a protein criticallyinvolved in DNA repair,
mitochondrial biogenesis, andregulating metabolic health.
SPEAKER_00 (20:11):
Aaron Powell Okay, so it keeps the cell running
cleanly.
SPEAKER_02 (20:14):
Precisely.
Alpha clotho is a membraneprotein largely produced in the
kidneys that acts as aco-receptor for fibroblast
growth factors, regulatingphosphate, and acting as a
powerful systemic antioxidant.
SPEAKER_00 (20:25):
So they're the good guys.
SPEAKER_02 (20:26):
Both of these proteins naturally decline as we
age, and they plummetdramatically in disease states
like diabetes.
They are essentially theguardians of youthful cellular
function.
SPEAKER_00 (20:37):
And the senolytic pulse brought them back online?
SPEAKER_02 (20:40):
It restored their expression levels significantly,
yes.
But here's the most crucialparadigm-shifting detail of that
entire mouse study.
The D plus Q treatment mitigatedthe kidney disease, reduced the
fibrosis, and restored thesegeroprotective proteins without
altering the mice's bloodglucose levels at all.
SPEAKER_00 (21:00):
Wait, wait, back up really.
I missed that.
So the mice were still fullydiabetic.
SPEAKER_02 (21:04):
Their blood sugar remained pathologically high the
entire time.
The primary metabolic insult wasstill present and active.
SPEAKER_00 (21:11):
That actually makes no sense until you think about
it.
The fire is still burning, theglucose is still thrashing the
system, but the kidney ishealing anyway.
How?
SPEAKER_02 (21:19):
Because it proves that the primary driver of the
tissue destruction isn't justthe high glucose, it's the
senescent cell's reaction to thehigh glucose.
The glucose triggers a few cellsto become senescent.
Those cells start pumping outSASP.
It's the SAP that drives themassive inflammation, the
fibrosis, and the suppression ofCR2N1 and alpha clotho.
(21:40):
By pulsing D plus Q and clearingout the zombie cells, they shut
off the secondary inflammatorycascade.
SPEAKER_00 (21:47):
Wow.
So you can't cure the diabeteswith D plus Q, but you can
basically bulletproof the tissueagainst the damage it causes by
keeping the inflammatorylandscape totally clean.
SPEAKER_02 (21:57):
Exactly.
It separates the chronologicalprogression of the Disease from
the biological decay of thetissue.
SPEAKER_00 (22:02):
Okay, that is wildly promising.
But as we always have to say onthis show, mice lie and monkeys
exaggerate.
SPEAKER_02 (22:08):
A classic phrasing, but true.
SPEAKER_00 (22:10):
Mice are great, but we are not mice.
What happens in humans?
And this brings us to the 2024Mayo Clinic Trial on Healthy
Human Women.
Because this one is, I mean,it's the reality check for the
whole field, isn't it?
SPEAKER_02 (22:22):
It absolutely is.
It is a vital study because itforces us to confront the
limitations of prophylacticpsynolytics.
SPEAKER_00 (22:28):
So break down the setup here.
This was led by Dr.
Sundeep Kosla, phase two,randomized control trial.
They took 60 healthypostmenopausal women and gave
them intermittent pulses ofdisatinib and quercetin for 20
weeks.
SPEAKER_02 (22:41):
Yes.
SPEAKER_00 (22:41):
And they were specifically looking at bone
metabolism.
Why bone?
SPEAKER_02 (22:45):
Because postmenopausal women experience
a sharp decline in circulatingestrogen.
Estrogen normally plays a keyrole in suppressing cellular
senescence in the bonemicroenvironment.
SPEAKER_01 (22:56):
Okay.
SPEAKER_02 (22:57):
So when estrogen drops, senescent cells
accumulate in the bone marrow,secreting SASP that actively
promotes osteoclasts, the cellsthat break down bone and inhibit
osteoblasts, the cells thatbuild new bone.
SPEAKER_00 (23:09):
Which causes osteoporosis.
SPEAKER_02 (23:11):
Exactly.
This is a primary driver ofpostmenopausal osteoporosis.
The hypothesis was that aprophylactic D plus Q pulse
would clear the senesin burdenand improve bone mineral
density.
SPEAKER_00 (23:22):
And when I read the top line results, it sounded
like a win.
The paper says D plus Q,increased bone formation markers
and decreased bone resorption.
But then you get into thesubgroup analysis, the fine
print, and it completely changesthe story.
SPEAKER_02 (23:34):
It does.
What did the subgroup analysisreveal?
SPEAKER_00 (23:37):
It showed that the drug combo only had a
significant benefit in the womenwho already had a demonstrably
high burden of senescent cellsat the start of the trial.
If a woman had low senescencemarkers at baseline, the D plus
Q basically did nothing for herbone density.
SPEAKER_02 (23:53):
Nothing beneficial, correct.
It introduces the concept of thesenescence threshold.
SPEAKER_00 (23:57):
But logically, if these zombie cells are bad,
shouldn't killing even a few ofthem be good?
If I'm a perfectly healthy45-year-old and I have just a
little bit of CSP happening, whywouldn't I want to clear it out
early?
SPEAKER_02 (24:09):
Because pharmacological intervention is
never free.
It always comes with abiological cost.
Right.
Dacinib is a powerful tyrosinekinase inhibitor.
Quaratin at those doses causesmassive oxidative stress.
If you have a low burden ofsenescent cells, the ambient
level of SASP in your tissuesisn't high enough to cause
significant systemicdysfunction.
SPEAKER_00 (24:31):
The noise of the alarm bells is quiet.
SPEAKER_02 (24:33):
Yes.
If you drop a systemic bomb likeD plus Q into that environment,
you are indiscriminatelyexposing your healthy cells to
the toxicity of the drugs forvery little therapeutic payoff.
SPEAKER_00 (24:46):
You're risking off-target effects when there's
no real enemy to fight yet.
SPEAKER_02 (24:49):
Precisely.
You are accepting all theclinical risk for a zero
measurable reward.
Dr.
Kosala's findings arguevehemently against the idea of
systemic synolytics as auniversal anti-aging
preventative.
SPEAKER_00 (25:02):
That makes total sense.
SPEAKER_02 (25:03):
If your biological age is relatively young and your
tissues aren't overrun,intervening with senolytics
could theoretically disruptnormal healthy tissue
homeostasis.
SPEAKER_00 (25:13):
Okay.
So if the perfectly healthypeople shouldn't be taking this,
who are the people with a highbaseline burden?
Who actually has an overrunsystem that needs an airstrike?
SPEAKER_02 (25:21):
Well, beyond the chronologically very old, the
target demographics arepopulations experiencing
accelerated aging.
The most prominent group wouldbe cancer survivors who have
undergone extensive chemotherapyor radiation therapy.
SPEAKER_00 (25:33):
Oh, because the chemo damages the cells.
SPEAKER_02 (25:35):
Immensely.
Doxerubicin, radiation, thesecause massive genotoxic stress.
They induce severe DNA damageacross the whole body.
Right.
To prevent that damage fromturning into secondary cancers,
huge swathes of the patient'scellular population pull the
emergency brake and entersenescence.
SPEAKER_00 (25:53):
So you survive the cancer, but the treatment
effectively force ages your bodyby filling it with zombie cells.
SPEAKER_02 (25:59):
Exactly.
This is why many childhoodcancer survivors suffer from
early onset frailty, prematureosteoporosis, and cardiovascular
disease in their 30s and 40s.
Their senescent burden isartificially and pathologically
high.
SPEAKER_00 (26:13):
And for them, clearing it out would be
life-changing.
SPEAKER_02 (26:15):
For that population, a synolytic protocol could be
utterly transformative.
Other groups include individualswith chronic viral infections
like HIV, severe metabolicsyndrome, or progeroid
syndromes, which are geneticdiseases that cause rapid aging.
SPEAKER_00 (26:29):
Right.
But for a healthy guy, buyingunregulated physetin capsules
off the internet.
SPEAKER_02 (26:33):
It is a waste of money and potentially a risk to
their health.
SPEAKER_00 (26:36):
Man, that is a tough pill to swallow for the
biohacker community, whichperfectly transitions us to the
state of the longevity biotechpipeline in 2026.
Because if systemic whole bodyanti-aging isn't working the way
we hoped, where's the moneyactually going?
SPEAKER_01 (26:49):
The field has had to pivot.
SPEAKER_00 (26:50):
Right.
And the longevity next report wereviewed was pretty stark about
this.
SPEAKER_02 (26:54):
It was a very sobering analysis.
The field has matured rapidly,and with that maturity comes the
realization that broad systemicclearance of senescent cells in
humans is fraught withcomplexities we haven't fully
solved yet.
SPEAKER_00 (27:08):
And the prime example of this was the massive
failure of UBX01 as a one.
This one hurt to read.
SPEAKER_02 (27:14):
It was a significant setback for Unity biotechnology,
yes.
SPEAKER_00 (27:17):
Aaron Powell They developed this drug specifically
for knee osteoarthritis, which,based on everything we just
talked about with cartilage andMMPs melting the floorboards,
sounds like the most logical,perfect target in the world.
You inject the senolytic rightinto the arthritic knee, it
kills the zombies, the SACTstops.
SPEAKER_01 (27:33):
That was the hypothesis.
SPEAKER_00 (27:35):
But it failed phase two clinical trials.
It couldn't beat a placebo forpain severity.
Why?
If the biology is so sound, whydid the clinical trial fail?
SPEAKER_02 (27:45):
Aaron Powell It is a profound lesson in the
difference between haltingtissue destruction and achieving
tissue regeneration.
We have to look at the anatomyof articular cartilage.
Okay.
Cartilage is in a vasculartissue, it does not have a
direct blood supply.
The chondrocytes, the cells thatmaintain the cartilage are
sparsely distributed and lockedwithin a dense collagen matrix.
SPEAKER_00 (28:05):
Aaron Powell Right.
They're like little islandssuspended in the gel.
SPEAKER_02 (28:08):
Yes.
Now, as osteoarthritisprogresses, the senescent
chondrocytes secrete MMPs thatirrevocably degrade that
collagen network.
By the time a patient isexperiencing severe chronic pain
and qualifies for a clinicaltrial, the structural
architecture of the knee jointis already devastated.
SPEAKER_00 (28:23):
Aaron Powell The floorboards are completely
rotted through.
SPEAKER_02 (28:26):
Precisely.
So Unity injects UBX01001.
The drug effectively clears thesenescent chondrocytes, the
localized SAC drops, the activechemical degradation stops.
SPEAKER_00 (28:37):
So it worked.
SPEAKER_02 (28:37):
Wait.
But and this is the criticalfailure point.
Clearing the senescent cellsdoes not magically regrow the
destroyed cartilage.
Because cartilage lacks a bloodsupply and a robust population
of stem cells, its regenerativecapacity is incredibly low.
SPEAKER_00 (28:53):
I get it.
You put out the fire in thehouse, but the house is still
burned down.
SPEAKER_02 (28:57):
Exactly.
SPEAKER_00 (28:57):
Putting out the fire doesn't rebuild the walls.
The patient is still walking onbone-on-bone friction.
SPEAKER_02 (29:02):
Exactly.
The senolytic achieved itsbiological endpoint.
It cleared the cells, but itfailed its clinical endpoint
because the tissue could notheal the structural deficit.
That's brutal.
The lesson here isn't thatsynolytics don't work, it's that
synolytics are not inherentlyregenerative medicine.
They prepare the biological soilby removing the toxic weeds, but
(29:23):
they do not plant the new seeds.
For tissues with poorregenerative capacity, clearing
the senescent cells late in thedisease process isn't enough to
reverse the pathology.
SPEAKER_00 (29:33):
That is just biology is so unforgiving.
So if systemic pills are toorisky for healthy people and
injecting worn-out jointsdoesn't rebuild the cartilage,
where is the actual successhappening right now?
SPEAKER_02 (29:44):
The successes are entirely found in precision,
localized applications intissues that do have
regenerative capacity, or wherehalting the inflammation
immediately restores function.
SPEAKER_01 (29:54):
Like where?
SPEAKER_02 (29:55):
Well, ironically, Unity Biotechnology provided the
perfect counterexample to theirarthritis failure with a
different drug, UBXREN325.
SPEAKER_00 (30:03):
Yes.
The eye injections.
I was reading the Behold andAspire study data on this, and
it's fascinating.
They targeted diabetic macularedema or DME.
Break down the pathology of DMEreally quickly so we understand
the target.
SPEAKER_02 (30:16):
In diabetic macular edema, the chronic high blood
glucose damages the delicateendothelial cells lining the
capillaries in the retina.
SPEAKER_01 (30:23):
Okay.
SPEAKER_02 (30:24):
This damage leads to hypoxia lack of oxygen.
The tissue responds byupregulating vascular
endothelial growth factor, orVEGF, trying to grow new blood
vessels.
But the environment is highlyinflamed and those endothelial
cells become senescent.
SPEAKER_00 (30:38):
So they pump out SASP.
SPEAKER_02 (30:39):
Yes.
They secrete SASP, which causesthe blood vessels to become
hyperpermeable.
They literally leak fluid andlipids into the macula, causing
swelling and severe vision loss.
SPEAKER_00 (30:50):
Okay, so the retina is swollen with leaky fluid
because of the zombie bloodvessels.
So Unity takes UBX1325, which isa BCL XL inhibitor.
It specifically blocks thatanti-apoptotic shield.
SPEAKER_01 (31:03):
Correct.
SPEAKER_00 (31:04):
And instead of giving it as a pill, they inject
it directly into the eyeball.
Intravitrial injection.
SPEAKER_01 (31:09):
A highly sequestered localized delivery mechanism.
SPEAKER_00 (31:13):
And it worked.
The patients actually gainedletters on the standard eye
chart.
Their vision improved and theretinal fluid decreased.
But the part I want to focus onis why they had to inject it
into the eye.
Because it comes back to theNivitoclax problem we danced
around earlier.
SPEAKER_01 (31:27):
Ah, yes.
SPEAKER_00 (31:28):
If BCL XL is the shield, why can't I just take a
BCL XL inhibitor pill to cure myeye?
SPEAKER_02 (31:33):
Because of your blood platelets.
Navidoclax is one of the mostpotent BCL XL inhibitors ever
discovered.
In vitro, it obliteratessenescent cells.
South great.
But as we discussed with thehit-and-run strategy, your
healthy blood platelets areutterly dependent on BCL XL to
survive their normal lifespan incirculation.
SPEAKER_00 (31:50):
The drug can't tell the difference between a zombie
cell shield and a plateletshield.
SPEAKER_02 (31:54):
Exactly.
And the molecule of Nivitoclaxdoesn't know where it is, it
just binds to BCL XL.
If you take Navitoclaxsystemically as an oral pill, it
enters your gastrointestinaltract, goes into your
bloodstream, and immediatelyencounters billions of
platelets.
SPEAKER_01 (32:08):
Oh no.
SPEAKER_02 (32:09):
It inhibits their BCL XL and the platelets undergo
apoptosis.
Before the drug ever reaches thesenescent cells in your retina,
it has caused catastrophicdose-limiting thrombocytopenia.
You would suffer severe internalbleeding.
SPEAKER_00 (32:23):
So the systemic route is a dead end for BCL XL
inhibitors.
But if you bypass thebloodstream entirely.
SPEAKER_02 (32:29):
Exactly.
By injecting UBX 1325 directlyinto the vitreous humor of the
eye, the drug remains localized.
It reaches high concentrationsin the retina, clears the
senescent vascular cells, shutsdown leaky vessels, and allows
the edema to resolve.
SPEAKER_01 (32:43):
That's brilliant.
SPEAKER_02 (32:44):
And because the eye is largely isolated from the
systemic circulation, the drugnever hits the platelets in your
bloodstream.
It is a masterpiece of precisionpharmacology.
SPEAKER_00 (32:53):
A biological sniper rifle.
And they're doing this with skinnow, too, right?
The 2026 biotech pipelinementioned Rubido Life Sciences
and a drug called RLS 1496.
SPEAKER_02 (33:03):
Yes, Rubedo is taking a similarly localized
approach.
RLS 1496 is formulated as atopical treatment, a cream or
ointment targetingdermatological conditions driven
by senescence.
SPEAKER_00 (33:14):
Like what?
SPEAKER_02 (33:15):
Things like chronic plaxoriasis or actinic
keratosis, which is a precursorto skin cancer caused by UV
damage.
SPEAKER_00 (33:23):
So again, you're not taking a pill.
You have a patch of severelydamaged, chronologically aged
skin, and you just apply thesenolytic directly to the
target.
It sinks in, causes the fentanreaction, or inhibits the
kinases locally, kills thezombies, and spares the rest of
your body.
SPEAKER_02 (33:38):
Precisely.
The field has evolved from theblunt force trauma of systemic
anti-aging into highlysophisticated localized
interventions.
Right.
The core science of cellularsenescence remains incredibly
robust.
The mechanisms are proven.
SASP degrades tissue, synolyticscan clear it.
But the translational realityrequires us to be meticulous
about how, when, and where wedeploy these agents.
(34:01):
We need highly specificbiomarkers to identify which
tissues are burdened, and weneed delivery systems that
minimize collateral damage.
SPEAKER_00 (34:08):
Man, it's just incredible to see how fast this
is moving, but also how complexthe reality is compared to the
headlines.
So let's pull all of thistogether for you listening right
now, whose brain is probablyoverflowing with acronyms.
SPEAKER_01 (34:21):
It is a lot of terminology to digest.
SPEAKER_00 (34:23):
We started with this wild sci-fi concept of zombie
cells.
Cells that get damaged, refuseto undergo apoptosis, and pull
the emergency brake, lockingthemselves into permanent cell
cycle arrest.
SPEAKER_02 (34:35):
And they survive by upregulating the BCL2 family of
proteins, creating a molecularshield that traps the
executioner enzymes and preventsthe mitochondria from initiating
cell death.
SPEAKER_00 (34:46):
Right.
And while they sit there,completely indencible, they
start skewing out the SSAP, thetoxic sludge of cytokines and
MMPs that literally melts theextracellular matrix around
them, causes massive chronicinflammation, and even infects
neighboring healthy cells,turning them into zombies too.
SPEAKER_02 (35:01):
Which leads us to the assassins.
Senolytics like dosetinib andquercetin, they bypass the
shields through targeted kinaseinhibition and exploiting the
senescent cells' own hoardedtransition metals.
SPEAKER_00 (35:12):
The fentan reaction.
SPEAKER_02 (35:13):
Yes, using the fentan reaction to generate
massive oxidative stress fromthe inside out.
SPEAKER_00 (35:18):
But because those biological pathways are shared
with healthy stem cells andplatelets, we have to use the
hit-and-run dosing protocol.
Pulse the drug, clear thetissue, let the drug wash out,
and give the healthy cells timeto regenerate the tissue.
SPEAKER_02 (35:31):
And while the preclinical data in murine
models of diabetic kidneydisease showed profound
restoration of geroprotectivefactors like CER2 and 1 without
even fixing the underlyingdiabetes.
SPEAKER_00 (35:42):
The human trials were the reality check.
SPEAKER_02 (35:44):
Yes.
The human clinical trials taughtus that systemic administration
is only beneficial if you have amassive pathological burden of
senescent cells, like a cancersurvivor post-chemotherapy.
SPEAKER_00 (35:55):
Right, leading to the 2026 reality where the big
wins are happening in precisionmedicine.
Eye injections for macularedema, toticle creams for skin
diseases, putting the sniperexactly where the target is.
SPEAKER_02 (36:05):
An incredibly thorough synthesis of a very
complex landscape.
SPEAKER_00 (36:16):
And it's kind of a mind-expanding way to look at
the future of human health.
SPEAKER_02 (36:20):
Oh.
I am curious to hear where yourmind has gone with this.
SPEAKER_00 (36:24):
Aaron Powell Well, we've always viewed aging as
this unstoppable whole-bodysystemic decline, like a tide
going out.
It happens to everything all atonce.
SPEAKER_02 (36:33):
Aaron Ross Powell The traditional view of aging,
yes.
SPEAKER_00 (36:35):
Aaron Powell But if CNLetics continue to evolve
exactly the way Unity and Rubedoare pushing them, these highly
localized, precise tools, maybeaging won't be seen as a
systemic failure anymore.
Maybe getting older will justbecome a series of localized
scheduled maintenanceappointments.
SPEAKER_02 (36:50):
Aaron Powell Hmm.
That shifts the paradigm frominevitable decay to managed
localized wear.
SPEAKER_00 (36:56):
Exactly.
Imagine it.
Imagine walking into aspecialized longevity clinic
when you're 70 years old.
You aren't there for a majorinvasive surgery, and you aren't
there to pick up a magic pillthat keeps you 25 forever.
You're just there to get thezombie cells cleaned out of a
specific area.
You get an injection in yourleft knee, some drops in your
retinas, maybe a topicaltreatment on your sun-damaged
(37:17):
shoulders.
You wait three days for theapoptosis to finish, the
inflammation clears, your stemcells rebuild the microscopic
damage, and you go about yourlife.
SPEAKER_02 (37:26):
Like routine servicing.
SPEAKER_00 (37:28):
It would be the exact same way you go to the
dentist every six months to getplaque scraped off your teeth
before it rots your gums.
Just routine localizedmaintenance.
SPEAKER_02 (37:37):
The conceptualization of senescence
as biological plaque is highlyresonant.
If we can develop the diagnosticimaging to accurately map the
senescent burden in real time,that future is entirely
plausible.
SPEAKER_00 (37:48):
What does human life actually look like when aging
isn't an inevitable full-bodytragedy, but just a routine
maintenance schedule?
Keep the diagnostics running,find the zombies, clear them
out, and go about your day.
SPEAKER_02 (38:00):
It is a profound question, and one the field of
geroscience is actively workingto answer.
SPEAKER_00 (38:05):
And we will be right here tracking it as it happens.
Thank you all so much for divingdeep into the biology of the
undead with us today.
Keep learning, keep questioning,and we'll catch you on the next
deep dive.
Popular Podcasts
Joy 101 with Hoda Kotb
Joy is essential. And it's also elusive. You can't order it, borrow it, or simply hope it into life. But now, there's a new and exciting way to start your journey toward a more joyful existence: The Joy 101 Podcast with Hoda! Best known for her Emmy-winning work and co-anchoring Today, Hoda Kotb infuses her authenticity, curiosity, and warmth into conversations with the world’s most fascinating people. Entertainment legends, sport icons, wellness experts, and everyday folks will share how they find, allow, and experience joy. Hoda will offer her own tips and takes on seeking a more balanced, harmonious life. If you're craving inspiration, support, and useful tools to maximize your joy, tune in to these candid, uplifting, and moving on-air chats. Joy after a breakup, joy as an empty-nester, joy after loss, joy as a caretaker — Hoda's new podcast will speak to you. Joy 101 with Hoda Kotb, an iHeartPodcast.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com